

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.
You can purchase shares of Arvinas (NASDAQ:ARVN) through any online brokerage.
Other companies in Arvinas’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Arvinas has a consensus price target of $19.60.
The stock price for Arvinas (NASDAQ: ARVN) is $7.31 last updated October 26, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Arvinas.
Arvinas does not have any upcoming earnings scheduled.
There is no upcoming split for Arvinas.
Arvinas is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade...